Invesco’s Acrivon Therapeutics ACRV Stock Holding History

Invesco’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-35,315	Closed	-$71.7K	–	3760
2025 Q1	$71.7K	Buy	+35,315	New	+$190K	﹤0.01%	3668

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Invesco's ACRV Position: Q2 2025 in Review

Invesco sold out of Acrivon Therapeutics (ACRV) in Q2 2025, closing a stake of 35,315 shares — an estimated $71.7K sold.

Invesco first reported a position in ACRV in Q1 2025 and held it in 1 quarter. The position peaked at $71.7K in Q1 2025. 53 funds tracked by Wall St. Rank hold ACRV as of Q2 2025.

Invesco reported no remaining Acrivon Therapeutics position as of Q2 2025 after selling out during the quarter.
Invesco sold 35,315 Acrivon Therapeutics shares in Q2 2025, an estimated $71.7K.
Invesco first reported a position in Acrivon Therapeutics in Q1 2025 and held it in 1 quarter.
Invesco's Acrivon Therapeutics position peaked at $71.7K in Q1 2025.
53 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2025.

Based on Invesco's 13F filing for Q2 2025, filed 13 Aug 2025.